FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Hosted on MSN6d
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares RiseThe stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...
She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...
Business Insider on MSN6d
The FDA is about to make weight-loss drugs a lot harder to getfrom sleep apnea to heavy drinking. The drugs became so popular so fast that manufacturers began running out, and patients ...
In a report released on January 24, David Low from J.P. Morgan maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of ...
UBS analyst Laura Sutcliffe maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – Research ...
Related FDA approves weight-loss drug Zepbound to treat sleep apnea FDA says shortage of GLP-1 drug tirzepatide is over Merck reaches weight-loss drug deal worth up to $2 billion with China-based ...
The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback